Small Intestinal Bacterial Overgrowth and Orocecal Transit Time in Patients of Inflammatory Bowel Disease
- 748 Downloads
Inflammatory bowel disease (IBD) consists of Ulcerative colitis (UC) and Crohn’s disease (CD). These two conditions share many common features—diarrhea, bloody stools, weight loss, abdominal pain, fever and fatigue. Small intestinal bacterial overgrowth (SIBO) is frequent in patients with CD but it has not been studied in UC Indian patients.
The study was planned to measure orocecal transit time (OCTT) and SIBO in UC and CD patients.
One hundred thirty-seven patients of IBD (95 UC and 42 CD) and 115 healthy controls were enrolled. OCTT and SIBO were measured by lactulose and glucose hydrogen breath test respectively. Concentration of hydrogen and methane were measured by SC microlyser from Quintron, USA.
Mean ± standard deviation (SD) of OCTT in patients of IBD was significantly higher as compared to controls. Furthermore, OCTT was significantly higher in CD patients as compared to UC patients. It was also observed that occurrence of SIBO was significantly higher in IBD patients as compared to controls. The occurrence of SIBO in CD (45.2 %) was significantly higher as compared to patients in UC (17.8 %) group. Percentage of methane positive IBD patients (2.9 %) was significantly lower as compared to methane positive controls (24.4 %).
OCTT was significantly delayed in IBD patients as compared to controls and in CD patients as compared to UC patients. OCTT was significantly higher in SIBO positive IBD patients as compared to SIBO negative patients. Thus, we can suggest that delayed OCTT would have been the cause of increased SIBO in these patients.
KeywordsSmall intestinal bacterial overgrowth Orocecal transit time Ulcerative colitis Crohn’s disease
The authors would like to acknowledge the financial support given by the Indian Council of Medical Research (ICMR), New Delhi, no 5/4/3-2/07/NCD II.
Conflict of interest
- 1.Kmiec Z. Cytokines in inflammatory bowel disease. Arch Immunol Ther Exp (Warsz). 1998;46:143–155.Google Scholar
- 2.Kathleen A, Jurenka JS. Inflammatory bowel disease part 1: ulcerative colitis pathophysiology and conventional and alternative treatment options. Altern Med Rev. 2003;8:247–283.Google Scholar
- 6.Binion DG, Fiocchi C. Immune modulation-is the environment important? In: McLeod RS, Martin K, Sutherland LR, Wallace JL, Williams CN, eds. Trends in Inflammatory Bowel Disease Therapy. Boston: Kluwer; 1996;39–48.Google Scholar
- 7.Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn’s disease. Gastroenterol Clin N Am. 1995;24:475–507.Google Scholar
- 9.Mishkin B, Yalovsky M, Mishkin S. Increased prevalence of lactose malabsorption in Crohn’s disease patients at low risk for lactose malabsorption based on ethnic origin. Am J Gastroentrol. 1997;92:1148–1153.Google Scholar
- 11.Toskes PP, Kumar A. Enteric bacterial flora and bacterial overgrowth syndrome. In: Sleisenger NH, Fordtran GS, eds. Gastrointestinal and Liver Disease Philadelphia. Philadelphia: WB Saunders; 1998:1523–1534.Google Scholar